Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

151.73 +3.04 (+2.04%)
Official Closing Price Updated: 7:00 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners. 
Via Benzinga
Is Johnson & Johnson the Best Dividend Stock for You?
J&J is the textbook blue chip stock -- but it's not for everyone. 
Via The Motley Fool
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Johnson & Johnson's Options: A Look at What the Big Money is Thinking
Via Benzinga
The Top 3 Sectors Poised For Growth This Summer
Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides. 
Via MarketBeat
Topics ETFs
NYSE:JNJ, an undervalued stock with good fundamentals.
JOHNSON & JOHNSON (NYSE:JNJ) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
Market Analysis: Johnson &amp; Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields. 
Via The Motley Fool
2 Top Stocks to Buy Now for Years of Passive Income
These tried-and-true businesses could be wise additions to your portfolio. 
Via The Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
From Johnson & Johnson
Via Business Wire
In-Depth Examination Of 11 Analyst Recommendations For Johnson & Johnson
Via Benzinga
How Is The Market Feeling About Johnson & Johnson?
Via Benzinga
Johnson & Johnson Faces New Lawsuit(s) Related To Its Talc Products
Johnson & Johnson faces a new class action lawsuit seeking damages and medical monitoring for cancer risk from talc products. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
From Beasley Allen
Via Business Wire
Johnson & Johnson's Arthritis Drug Shows Potential In Crohn's Disease
Johnson & Johnson announced that their Phase 3 GRAVITI study of Tremfya (guselkumab) SC therapy for Crohn's disease met all primary and secondary endpoints. 
Via Benzinga
3 Healthcare Stocks to Buy Now: June 2024
Invest in healthcare stocks to buy now, benefiting from robust product pipelines and tech advancements at this time. 
Via InvestorPlace
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
Discover these blue-chip stocks to buy in the biotechnology, banking, pharmaceuticals, tobacco, restaurants, and entertainment industries. 
Via InvestorPlace
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
These healthcare players offer you dividends and a strong earnings picture. 
Via The Motley Fool
3 No-Brainer Stocks to Buy With $500 Right Now
A modest amount of money can go a long when when it's put to work in game-changing businesses with well-defined catalysts. 
Via The Motley Fool
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
We ran a screener using Benzinga Pro to filter out three mega-cap stocks that are currently trading at attractive valuations. 
Via Benzinga
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
From Beasley Allen
Via Business Wire
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product. 
Via Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for... 
Via Benzinga
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
The 7 Best Under $20 Stocks to Buy in June 2024
Stocks may be ready to rally, here are seven of the best under $20 stocks to buy for those who still want value. 
Via InvestorPlace
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
From FN Media Group LLC
Via GlobeNewswire
Blue-Chip Jackpots: 3 Top-Notch Stocks at Bottom-Barrel Prices
Discover three beaten-down blue-chip stocks, including Johnson & Johnson, McDonald's and Accenture, with upside potential. 
Via InvestorPlace
Payout Powerhouses: 7 Dividend Stocks to Buy Now
Although growth ideas will probably always attract the market’s attention, it’s useful to balance your holdings with dividend stocks to buy. 
Via InvestorPlace
Dividend Heaven: 7 Standout Stocks for Income Investors to Buy in June
Here are three dividend stocks to buy for your retirement portfolio that should offer rising income beyond the rate of inflation. 
Via InvestorPlace
Topics Retirement
Exposures Pension
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.